Medical condition
Hereditary Angioedema
Hereditary Angioedema is a medical condition tracked by NovaPharmaNews across 8 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- sebetralstat (EKTERLY) Blood and blood forming organs (B06)
- berotralstat (ORLADEYO) Blood and blood forming organs (B06)
- icatibant (CIPLA ICATIBANT) Blood and blood forming organs (B06)
- lanadelumab (TAKHZYRO) Blood and blood forming organs (B06)
- c1 inhibitor (human) (CINRYZE) Blood and blood forming organs (B06)
- donidalorsen (DAWNZERA) Blood and blood forming organs (B06)
- conestat alfa (RUCONEST) Blood and blood forming organs (B06)
- garadacimab (ANDEMBRY) Blood and blood forming organs (B06)
Latest Hereditary Angioedema news
Intellia Therapeutics Submits FDA Application for Lonvo-Z, First CRISPR Gene Therapy for Hereditary Angioedema
Intellia initiates rolling BLA submission for lonvo-z, a potential one-time CRISPR treatment for hereditary angioedema, marking a breakthrough in gene therapy.
Intellia Therapeutics Achieves First-Ever Positive Phase 3 Results for In Vivo Gene Editing with Lonvoguran Ziclumeran in Hereditary Angioedema
Intellia's lonvoguran ziclumeran becomes first in vivo gene editing therapy to succeed in Phase 3, offering potential one-time cure for hereditary angioedema patients.